1 / 31

From darkness to light: prospects for therapy for childhood retinal disease Anthony T Moore

From darkness to light: prospects for therapy for childhood retinal disease Anthony T Moore Moorfields Eye Hospital and Institute of Ophthalmology UCL. Retinal dystrophies: pathways to therapy. clinical phenotype. gene mapping. protein function. animal models. Human treatment trials. UCL.

thane
Download Presentation

From darkness to light: prospects for therapy for childhood retinal disease Anthony T Moore

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. From darkness to light: prospects for therapy for childhood retinal disease Anthony T Moore Moorfields Eye Hospital and Institute of Ophthalmology UCL

  2. Retinal dystrophies: pathways to therapy clinical phenotype gene mapping protein function animal models Human treatment trials

  3. UCL Clinical trial of gene therapy for early-onset severe retinal degeneration caused by defects in RPE65 JWB Bainbridge, AJ Smith, SS Barker, S Robbie, R Henderson, K Balaggan, A Viswanathan, GE Holder, A Stockman, N Tyler, S Petersen-Jones, SS Bhattacharya, AJ Thrasher, FW Fitzke, BJ Carter, GS Rubin, AT Moore, RR Ali and the Moorfields Eye Hospital and UCL Eye Gene Therapy Study Group Institute of Ophthalmology, University College London Moorfields Eye Hospital NHS Foundation Trust, London NIHR Biomedical Research Centre for Ophthalmology, University College London and Moorfields Eye Hospital London Department of Civil and Environmental Engineering , University College London Michigan State University, MI Institute of Child Health, University College London Targeted Genetics Corporation, Seattle Bainbridge J et al N Eng J Med 2008 April [Epub]

  4. Lebers amaurosis • first described 1869 • infantile onset rod-cone dystrophy • 2-3 per 100,000 live births • 5% of congenital blindness • AR inheritance • genetically heterogenous • poor vision from infancy • nystagmus • non-recordable ERG

  5. Courtesy of Professor Birgit Lorenz LCA Genes Lebercilin CPE290 RDH12

  6. RPE65 1p31.2 • 14 exons • Encodes a 65 KD protein within RPE • Crucial to Vit A metabolism in retina • responsible for isomerisation of all-trans retinol to 11-cis retinol • Mutations cause disease in man (6% LCA) • mouse knockout • Canine model • Gene therapy rescue in mice and dogs

  7. Phenotype associated with RPE65 mutations • Infantile onset of visual impairment • Light staring • Profound night blindness • Useful vision at young age • Absent rod function • Residual cone function • Progression to severe visual loss in late teens • Late cell death

  8. Subject RJ age 21 VA Rt 2/48 (1.38) Lt 2/60 (1.48) Poor colour vision Visual field loss Non recordable ERG

  9. RPE65 gene therapy for LCA • • Single gene loss-of-function defect • • Condition is severe and has predictably poor prognosis • • Window of opportunity for intervention • • Intervention might improve function • • Target RPE cells can be transduced efficiently by rAAV • • Principle is proven in experimental models • UK human trial funded by 970K grant from Department of Health gene therapy intiative

  10. Design of clinical trial of RPE65 gene therapy for LCA • Aim: to determine whether gene therapy for retinal dystrophy caused by RPE65 mutations is safe and effective in humans • Study design phase I/II open-label single-centre dose-escalation study • IMP rAAV2.hRPE65p.hRPE65 • Primary outcome safety • Secondary outcome evidence of visual benefit

  11. Design of clinical trial of RPE65 gene therapy for LCA Inclusion criteria: • early-onset severe retinal dystrophy • missense mutations in RPE65 • between 8 and 30 yrs of age • in each case, the eye with the worse acuity was selected as the study eye Exclusion criteria: • visual acuity better than 20/120 in the study eye • null mutation in RPE65 • contra-indications for systemic immune suppression

  12. Trial stages and dose-escalation Stage 1 of the trial involved: • 3 young adults (aged 16 to 30 years) with advanced degeneration • subretinal injection involving up to 1/3 the total retinal area Subsequent stages will involve: • 9 subjects younger than 16 yrs • dose escalation involving larger areas of the retina

  13. Baseline characteristics of subjects

  14. Subretinal injection of rAAV2.hRPE65p.hRPE65 (1x1011/ml; 1ml)

  15. Resolution of induced retinal detachment during surgery pre-op +1 day +4 months # 1 # 2 # 3

  16. Resolution of induced retinal detachment Pre-op +1 day +2 days # 1 scan unrecordable # 2 # 3

  17. Adverse events Transient visual loss (associated with induced retinal detachment) Mild post operative inflammation No surgical complications No immune response to vector or RPE65

  18. Visual acuity following subretinal injection

  19. Microperimetry Subject #1 Subject #2 Subject #3 control eye study eye control eye study eye study eye control eye

  20. Microperimetry: Subject #3; 6 months following surgery study eye control eye

  21. Microperimetry: Subject #3; 6 months following surgery study eye control eye

  22. Microperimetry: Subject #3; 6 months following surgery study eye control eye

  23. Dark-adapted perimetry; change in sensitivity over 6 months study eye #1 control eye #2 control eye study eye study eye #3 control eye Field of left eye Field of right eye

  24. Dark-adapted perimetry: Subject #3; 6 months following surgery Positive slope P<0.01 P<0.05 P<0.1 P>= 0.1 Negative slope P >= 0.1 P<0.1 P< 0.05 P< 0.01 P< 0.001 study (right) eye control (left) eye

  25. Dark-adapted perimetry: Subject #3; 6 months following surgery Positive slope P<0.01 P<0.05 P<0.1 P>= 0.1 Negative slope P >= 0.1 P<0.1 P< 0.05 P< 0.01 P< 0.001 study (right) eye control (left) eye

  26. Assessment of visually-guided mobility: UCL Pedestrian Accessibility & Movement Environment Laboratory

  27. Assessment of visually-guided mobility Subject #1 Subject #2 Subject #3 4 lux 4 lux 4 lux 240 lux 240 lux 240 lux

  28. Assessment of visually-guided mobility Subject #3; 6 months following surgery 4 lux

  29. Visually-guided mobility: Subject #3; 6 months following surgery

  30. Conclusions • Subretinal vector injection is safe • Even in advanced retinal degeneration, rAAV2.hRPE65p.hRPE65 can improve vision • These results support further studies in children with RPE65 defects

  31. UCL Acknowledgements The Moorfields Eye Hospital / UCL Eye Gene Therapy Study Group; G.W. Aylward, D. Boampong, C. Broderick, P. Buch, C. Childs, Y. Duran, D. Ehlich, S. Falk, M. Feely, T. Fujiyama, F. Ikeji, V. Luong, A. Milliken, R. Maclaren, P. Moradi, F. Mowat, M. Richardson, C. Ripamonti, A.G. Robson, H. Rostron, I. Russell-Eggitt, P. Schlottmann, M. Tschernutter and N. Wasseem. Andrew Dick and The UK RPE65 Gene Therapy Data Safety Monitoring Committee Alan Bird, Andrew Webster and Zdenek Gregor: Moorfields RPE65 Gene Therapy Advisory Committee Vivien Perry and Moorfields Pharmaceuticals Graeme Black and the Manchester Regional Genetics Laboratory David Wong The patients and their families Funding UK Department of Health The British Retinitis Pigmentosa Society Special Trustees of Moorfields Eye Hospital The Sir Jules Thorn Charitable Trust The European Union (EVI Genoret and Clinigene programmes) The Wellcome Trust The Medical Research Council Foundation Fighting Blindness USA Fight for Sight The Ulverscroft Foundation Fighting Blindness Ireland Moorfields Eye Hospital and UCL Institute of Ophthalmology Biomedical Research Centre for Ophthalmology JWBB is a Wellcome Advanced Fellow; AJT is a Wellcome Senior Fellow

More Related